Evidence map›Paper›PMID 33559681›Full record

ArticleBrain : a journal of neurology2021

An ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy.

Alistair T Pagnamenta, Rauan Kaiyrzhanov, Yaqun Zou, Sahar I Da'as, Reza Maroofian, Sandra Donkervoort, Natalia Dominik, Marlen Lauffer, Matteo P Ferla, Andrea Orioli and 45 more

Open access · hybridAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Extracellular Matrix Remodeling in Motor Neuron Diseases.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Modeling of Charcot-Marie-Tooth disease in zebrafish.Frontiers in molecular neuroscience · 2025
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

55 authors at 20 institutions in 7 countries.

Alistair T PagnamentaNIHR Biomedical Research Centre, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Rauan KaiyrzhanovDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, UK.
Yaqun ZouNeuromuscular and Neurogenetic Disorders of Childhood Section, NINDS, National Institutes of Health, Bethesda, MD, USA.
Sahar I Da'asDepartment of Human Genetics, Sidra Medicine, Doha, Qatar.
Reza MaroofianDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, UK.
Sandra DonkervoortNeuromuscular and Neurogenetic Disorders of Childhood Section, NINDS, National Institutes of Health, Bethesda, MD, USA.
Natalia DominikDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, UK.
Marlen LaufferInstitute of Human Genetics, Center for Molecular Medicine Cologne (CMMC), Institute of Genetics, and Center for Rare Diseases Cologne, University of Cologne, Cologne, Germany.
Matteo P FerlaNIHR Biomedical Research Centre, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Andrea OrioliWilliam Harvey Research Institute, Queen Mary University of London, London, UK.
Adam GiessWilliam Harvey Research Institute, Queen Mary University of London, London, UK.
Arianna TucciWilliam Harvey Research Institute, Queen Mary University of London, London, UK.
Christian BeetzCentogene AG, Rostock, Germany.
Maryam SedghiMedical Genetics Laboratory, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Behnaz AnsariDepartment of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Rita BarresiThe John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle, UK.
Keivan BasiriDepartment of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Andrea CorteseDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, UK.
Greg ElgarWilliam Harvey Research Institute, Queen Mary University of London, London, UK.
Miguel A Fernandez-GarciaDepartment of Paediatric Neurology - Neuromuscular Service, Evelina Children's Hospital, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Janice YipDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, UK.
A Reghan FoleyNeuromuscular and Neurogenetic Disorders of Childhood Section, NINDS, National Institutes of Health, Bethesda, MD, USA.
Nicholas GutowskiDepartment of Neurology, Royal Devon and Exeter NHS Trust, Exeter, UK.
Heinz JungbluthDepartment of Paediatric Neurology - Neuromuscular Service, Evelina Children's Hospital, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Saskia LasscheDonders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands.
Tim LavinDepartment of Neurology, Salford Royal NHS Foundation Trust, Manchester, UK.
Carlo MarcelisDepartment of Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands.
Peter MarksWest Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, UK.
Chiara Marini-BettoloThe John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle, UK.
Livija MedneDivisions of Neurology and Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Ali-Reza MoslemiDepartment of Pathology, University of Gothenburg, Sahlgrenska University Hospital, Sweden.
Anna SarkozyThe Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, UCL Great Ormond Street Institute of Child Health, and Great Ormond Street Hospital Trust, London, UK.
Mary M ReillyDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, UK.
Francesco MuntoniThe Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, UCL Great Ormond Street Institute of Child Health, and Great Ormond Street Hospital Trust, London, UK.
Francisca MillanGeneDx, Gaithersburg, 20877 MD, USA.
Colleen C MurareskuMitochondrial Medicine Frontier Program, Division of Human Genetics, Children's Hospital of Philadelphia, PA, USA.
Anna C NeedWilliam Harvey Research Institute, Queen Mary University of London, London, UK.
Andrea H NemethNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Sarah B NeuhausNeuromuscular and Neurogenetic Disorders of Childhood Section, NINDS, National Institutes of Health, Bethesda, MD, USA.
Fiona NorwoodDepartment of Neurology, King's College Hospital, London, UK.
Marie O'DonnellWest Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, UK.
Mary O'DriscollWest Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, UK.
Julia RankinPeninsula Clinical Genetics Service, Royal Devon and Exeter NHS Trust, Exeter, UK.
Sabrina W YumDivision of Pediatric Neurology, The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Zarazuela Zolkipli-CunninghamMitochondrial Medicine Frontier Program, Division of Human Genetics, Children's Hospital of Philadelphia, PA, USA.
Isabell BrusiusInstitute of Human Genetics, Center for Molecular Medicine Cologne (CMMC), Institute of Genetics, and Center for Rare Diseases Cologne, University of Cologne, Cologne, Germany.
Gilbert WunderlichDepartment of Neurology, Center for Rare Diseases Cologne, University Hospital Cologne, Cologne, Germany.
Genomics England Research Consortium
Mert KarakayaInstitute of Human Genetics, Center for Molecular Medicine Cologne (CMMC), Institute of Genetics, and Center for Rare Diseases Cologne, University of Cologne, Cologne, Germany.
Brunhilde WirthInstitute of Human Genetics, Center for Molecular Medicine Cologne (CMMC), Institute of Genetics, and Center for Rare Diseases Cologne, University of Cologne, Cologne, Germany.
Khalid A FakhroDepartment of Human Genetics, Sidra Medicine, Doha, Qatar.
Homa TajsharghiSchool of Health Science, Division Biomedicine and Translational Medicine, University of Skovde, Sweden.
Carsten G BönnemannNeuromuscular and Neurogenetic Disorders of Childhood Section, NINDS, National Institutes of Health, Bethesda, MD, USA.
Jenny C TaylorNIHR Biomedical Research Centre, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Henry HouldenDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, UK.
Queen Mary University of London · GBNational Hospital for Neurology and Neurosurgery · GBNational Institutes of Health · USUniversity of Cologne · DEBirmingham Women’s and Children’s NHS Foundation Trust · GBChildren's Hospital of Philadelphia · USCentre for Human Genetics · GBIsfahan University of Medical Sciences · IRKing's College Hospital · GBCentogene (Germany) · DEGreat Ormond Street Hospital · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBRadboud University Nijmegen · NLRoyal Devon & Exeter NHS Foundation Trust · GBSalford Royal NHS Foundation Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBHamad bin Khalifa University · QAKing's College London · GBSahlgrenska University Hospital · SEUniversity Hospital Cologne · DE

Funding

Molecular and Clinical Manifestations of Matrix and Aggregate MyopathiesZIANS003129 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI BÖNNEMANN, CARSTEN · 2011 to 2025
$52.8M
Medical Research Council MC_EX_MR/M009203/1Medical Research Council MC_PC_14089Medical Research Council MR/M009203/1Medical Research Council MR/S006753/1Medical Research Council MR/T001712/1Wellcome Trust 203141/Z/16/Z
6 · The paper itself

Abstract

The extracellular matrix comprises a network of macromolecules such as collagens, proteoglycans and glycoproteins. VWA1 (von Willebrand factor A domain containing 1) encodes a component of the extracellular matrix that interacts with perlecan/collagen VI, appears to be involved in stabilizing extracellular matrix structures, and demonstrates high expression levels in tibial nerve. Vwa1-deficient mice manifest with abnormal peripheral nerve structure/function; however, VWA1 variants have not previously been associated with human disease. By interrogating the genome sequences of 74 180 individuals from the 100K Genomes Project in combination with international gene-matching efforts and targeted sequencing, we identified 17 individuals from 15 families with an autosomal-recessive, non-length dependent, hereditary motor neuropathy and rare biallelic variants in VWA1. A single disease-associated allele p.(G25Rfs*74), a 10-bp repeat expansion, was observed in 14/15 families and was homozygous in 10/15. Given an allele frequency in European populations approaching 1/1000, the seven unrelated homozygote individuals ascertained from the 100K Genomes Project represents a substantial enrichment above expected. Haplotype analysis identified a shared 220 kb region suggesting that this founder mutation arose >7000 years ago. A wide age-range of patients (6-83 years) helped delineate the clinical phenotype over time. The commonest disease presentation in the cohort was an early-onset (mean 2.0 ± 1.4 years) non-length-dependent axonal hereditary motor neuropathy, confirmed on electrophysiology, which will have to be differentiated from other predominantly or pure motor neuropathies and neuronopathies. Because of slow disease progression, ambulation was largely preserved. Neurophysiology, muscle histopathology, and muscle MRI findings typically revealed clear neurogenic changes with single isolated cases displaying additional myopathic process. We speculate that a few findings of myopathic changes might be secondary to chronic denervation rather than indicating an additional myopathic disease process. Duplex reverse transcription polymerase chain reaction and immunoblotting using patient fibroblasts revealed that the founder allele results in partial nonsense mediated decay and an absence of detectable protein. CRISPR and morpholino vwa1 modelling in zebrafish demonstrated reductions in motor neuron axonal growth, synaptic formation in the skeletal muscles and locomotive behaviour. In summary, we estimate that biallelic variants in VWA1 may be responsible for up to 1% of unexplained hereditary motor neuropathy cases in Europeans. The detailed clinical characterization provided here will facilitate targeted testing on suitable patient cohorts. This novel disease gene may have previously evaded detection because of high GC content, consequential low coverage and computational difficulties associated with robustly detecting repeat-expansions. Reviewing previously unsolved exomes using lower QC filters may generate further diagnoses.

Indexed as

AdultAgedAnimalsBehavior, AnimalChildExtracellular Matrix ProteinsFemaleHereditary Sensory and Motor NeuropathyHumansMaleMiddle AgedMuscle, SkeletalMutationPedigreeYoung AdultZebrafishExtracellular Matrix ProteinsVWA1 protein, humanEMGgenetics: neuropathyhereditary motor and sensory neuropathiesnerve conduction studieswhole-genome sequencing

Identifiers

PMID33559681
PMCPMC8263055
OpenAlexW3122083512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.